Impact of treatment for opioid dependence on fatal drug-related poisoning: A national cohort study in England

Addiction

Volumn 111, Issue 2, 2016, Pages 298-308

  Pierce, Matthias ^a   Bird, Sheila M ^b   Hickman, Matthew ^c   Marsden, John ^d   Dunn, Graham ^a   Jones, Andrew ^a   Millar, Tim ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MRC BIOSTATISTICS UNIT   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Drug related poisoning; Opiate dependence; Opioid agonist pharmacotherapy; Overdose; Psychosocial treatment; Residential treatment

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC AGENT; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG OVERDOSE; ENGLAND; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROCEDURES; PSYCHOTHERAPY; YOUNG ADULT;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; COHORT STUDIES; COMBINED MODALITY THERAPY; DRUG OVERDOSE; ENGLAND; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PSYCHOTHERAPY; YOUNG ADULT;

EID: 84954361017     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13193     Document Type: Article

References (36)

1. Degenhardt L., Whiteford H. A., Ferrari A. J., Baxter A. J., Charlson F. J., Hall W. D. et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1564-74.
2. Merrall E. L. C., Bird S. M., Hutchinson S. J. Mortality of those who attended drug services in Scotland 1996-2006: record-linkage study. Int J Drug Policy 2012; 23: 24-32.
3. Pierce M., Bird S. M., Hickman M., Millar T. National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005-2009. Drug Alcohol Depend 2015; 146: 17-23.
4. Bargagli A. M., Hickman M., Davoli M., Perucci C. A., Schifano P., Buster M. et al. Drug-related mortality and its impact on adult mortality in eight European countries. Eur J Public Health 2006; 16: 198-202.
5. Degenhardt L., Bucello C., Mathers B., Briegleb C., Ali H., Hickman M. et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011; 106: 32-51.
6. Mattick R. P., Breen C., Kimber J., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2: CD002207.
7. Mattick R. P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; 3: CD002209.
8. Amato L., Davoli M., Minozzi S., Ferroni E., Ali R., Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2013; 2: CD003409.
9. World Health Organization Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization; 2009.
10. National Institute for Health and Clinical Excellence. Methadone and buprenorphine for the management of opioid dependence. NICE Technology Appraisal Guide 114. 2007. Available at: http://www.nice.org.uk/guidance/ta114 (Archived by WebCite® at: http://www.webcitation.org/6bExK9Teh) (accessed 2 September 2015).
11. Kleber H. D., Weiss R. D., Anton R. F. Jr, George T. P., Greenfield S. F., Kosten T. R. et al. Treatment of Patients With Substance Use Disorders, 2nd edn. American Psychiatric Association. Am J Psychiatry 2007; 164: 5-123.
12. National Institute for Health and Clinical Excellence. Drug Misuse: Psychosocial interventions. London: National Institute for Health and Clinical Excellence; 2007.
13. White M., Burton R., Darke S., Eastwood B., Knight J., Millar T. et al. Fatal opioid poisoning: a counterfactual model to estimate the preventive effect of treatment for opioid use disorder in England. Addiction 2015. published online 1 May. doi: 10.1111/add.12971.
14. Degenhardt L., Randall D., Hall W., Law M., Butler T., Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009; 105: 9-15.
15. Cornish R., Macleod J., Strang J., Vickerman P., Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010; 341: c5475.
16. Turner R. M., Bird S. M., Higgins J. P. The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PLOS ONE 2013; 8: e59202.
17. Grella C. E., Lovinger K. 30-Year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California. Drug Alcohol Depend 2011; 118: 251-8.
18. McCowan C., Kidd B., Fahey T. Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study. BMJ 2009; 338: b2225.
19. National Treatment Agency for Substance Misuse. Statistics from the National Drug Treatment Monitoring System (NDTMS) 1 April 2010-31 to March 2011. London: Department of Health; 2011.
20. Marsden J., Eastwood B., Jones H., Bradbury C., Hickman M., Knight J. et al. Risk adjustment of heroin treatment outcomes for comparative performance assessment in England. Addiction 2012; 107: 2161-72.
21. Department of Health. Improving outcomes and supporting transparency. Part 1: A public health outcomes framework for England, 2013-2016. 2013. Available at: http://www.rcpsych.ac.uk/pdf/The%20Public%20Health%20Outcomes%20Framework.pdf (Archived by WebCite® at: http://www.webcitation.org/6bExVLJn2) (accessed 2 September 2015).
22. Home Office. Drug Strategy 2010 Reducing Demand, Restricting Supply, Building Recovery: Supporting People to Live a Drug Free Life. London: Home Office; 2010.
23. Millar T., Ahmad M., Richardson A., Skodbo S., Donmall M., Jones A. The Drug Data Warehouse: Linking Data on Drug Misusers and Drug-Misusing Offenders. London: Home Office; 2012.
24. Marsden J., Eastwood B., Bradbury C., Dale-Perera A., Farrell M., Hammond P. et al. Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study. Lancet 2009; 374: 1262-70.
25. National Drug Treatment Monitoring System. Implementation guide for adult drug and alcohol treatment providers. Available at: http://www.nta.nhs.uk/uploads/guidetoimplementingcdsjv2.0.pdf (Archived by WebCite® at: http://www.webcitation.org/6bExdWmhp) (accessed 2 September 2015).
26. Bird S. M. Counting the dead: properly and promptly. Lancet 2013; 381: 1719.
27. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10). Geneva: World Health Organization; 1992.
28. Clark R. E., Samnaliev M., Baxter J. D., Leung G. Y. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff 2011; 30: 1425-33.
29. Merrall E. L. C., Kariminia A., Binswanger I. A., Hobbs M. S., Farrell M., Marsden J. et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction 2010; 105: 1545-54.
30. Naeem F., Bhatti F., Pickering R., Kingdon D. A controlled trial of the effectivness of drug treatment and testing orders (DTTO) with standard care. J Subst Abuse Treat 2007; 12: 253-65.
31. Skodbo S., Brown G., Deacon S., Cooper A., Hall A., Millar T. The Drug Intervention Programme (DIP): Addressing Drug Use and Offending Through 'Tough Choices'. Home Office Research Report. London: Home Office; 2007.
32. Best D., Wood K., Sweeting R., Morgan B., Day E. Fitting a quart into a black box: keyworking in quasi-coercive drug treatment in England. Drugs Educ Prev Policy 2010; 17: 370-87.
33. Kimber J., Larney S., Hickman M., Randall D., Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry 2015; 2: 851-948.
34. Strang J., McCambridge J., Best D., Beswick T., Bearn J., Rees S. et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 2003; 326: 959-60.
35. Millar T., Hayhurst K. P., Jones A., Pierce M., Davies L., Weston S. et al. Factors associated with receipt of residential rehabilitation by opiate users indicate that these clients are more amenable to drug treatment. Drugs Educ Prev Policy 2014; 21: 165-72.
36. Hickman M., Vickerman P., Robertson R., Macleod J., Strang J. Promoting recovery and preventing drug-related mortality: competing risks? J Public Health 2011; 33: 332-4.